Abstract:
Technology provided herein relates in part to methods, processes, machines and apparatuses for detecting genetic variations. In some embodiments, the technology is related to non-invasive assessment of aneuploidies.
Abstract:
Die Erfindung betrifft Verfahren und Mittel zur Diagnostik von Tumoren, insbesondere zur Frühdiagnostik(Vorsorge)und zur Unterscheidung von benignen und malignen Tumoren mittels PCR, insbesondere in Körperflüssigkeiten. Das erfindungsgemäße Verfahren zeichnet sich durch eine Kombination einer Präamplifikation mittels PCR aus,in der methylierte DNA-Sequenzen stärker amplifiziert werden als nicht-methylierte DNA-Sequenzenund eine anschließende Quantifizierung mittels einer speziellen digitalen PCR, in der deutlich mehr DNA eingesetzt wird, als nach dem Stand der Technik üblich. Wie anhand von Vergleichsdaten gezeigt wird, ermöglicht die Erfindung vorteilhaft eine deutlich zuverlässige Aussage, ob eine maligne Tumorerkrankung vorliegt oder nicht. Die Erfindung eignet sich zum Screening (Vorsorge), zur Verlaufskontrolle einer Tumorerkrankung, insbesondere zum Ausschluss einerminimalen Resterkrankung (MRD) und zur Differentialdiagnose von malignen Karzinomen von benignen Tumoren.
Abstract:
The present invention discloses methods for identification of oligonucleotides by manipulation of the information content a plurality of oligonucleotides. A main object of the methods is the identification of new molecular activity such as new ligands of interest for the development of therapeutics or in the field of nanotechnology.
Abstract:
Embodiments are provided that relate to methods, systems, kits, computer-readable medium, and apparatuses comprising a computer-based variant calling model that incorporates the viable template count of the aliquot in calling a sequence of a target region based on a set of sequence reads.
Abstract:
This disclosure provides, among other things, methods for generating and applying therapeutic interventions. The methods involve, for example, (a) sequencing polynucleotides from cancer cells from a subject; (b) identifying and quantifying somatic mutations in the polynucleotides; (c) developing a profile of tumor heterogeneity in the subject indicating the presence and relative quantity of a plurality of the somatic mutations in the polynucleotides, wherein different relative quantities indicates tumor heterogeneity; and (d) determining a therapeutic intervention for a cancer exhibiting the tumor heterogeneity, wherein the therapeutic intervention is effective against a cancer having the profile of tumor heterogeneity determined.
Abstract:
The present disclosure provides systems and methods for the optical detection of a plurality of labeled substrates in an assay. The various aspects of the optical detection systems enable the simultaneous detection of the plurality of labeled substrates. These systems are particularly useful in the detection of nucleic acids during an amplification reaction.
Abstract:
The present invention provides a method for detecting a genetic variant in a region of interest in a DNA sample comprising (i) determining, for a given sequencing platform, sequencing process and sequencing depth, the distribution of the number of reads supporting a genetic variant or plurality of genetic variants expected to be observed in the sequencing results of amplification reactions due to amplification and sequencing error (read count distribution); (ii) based on the read count distribution determined in step (i), establishing a threshold frequency at or above which the genetic variant must be observed in sequencing results of amplification reactions to assign a positive determination for the presence of the genetic variant in a given amplification reaction; (iii) partitioning the DNA sample into a plurality of replicate amplification reactions, so that the mean number of amplifiable template molecules of the region of interest in a replicate amplification reaction is fewer than the reciprocal of the threshold frequency determined in step (ii); (iv) performing the amplification reactions of step (iii) and sequencing the products of amplification reactions, (v) based on step (ii) and the results of step (iv), determining the presence/absence of the genetic variant in each replicate amplification reaction; and (vi) integrating the results of (v) to determine the presence/absence of the genetic variant in the region of interest in the DNA sample.
Abstract:
A method for quantifying nucleic acid is provided. The method includes determining a first reference threshold cycle for a first predetermined input quantity for a reference nucleic acid, determining a first target threshold cycle for the first predetermined input quantity for a target nucleic acid, determining a second reference threshold cycle for a second predetermined input quantity for the reference nucleic acid, and determining a second target threshold cycle, by the processor, for the second predetermined input quantity for the target nucleic acid. The method further includes receiving a sample threshold cycle, determining a sample input quantity based on the first and second reference threshold cycle and the first and second target threshold cycle, and displaying the sample input quantity to a user.
Abstract:
The present disclosure relates to characterization of biological samples by amplification detection in a porous substrate. By way of example, a porous substrate may include amplification reagents configured to provide a signal when released during amplification. When a sample is applied, amplification occurs as a wavefront from the application point, and the time that the wavefront reaches a distance on the porous substrate is related to an initial concentration of the sample applied. By detecting the distance travelled by the amplification products at one or more time points, an initial concentration of the sample may be estimated.